Project Funding
Ecrit par Rare Disease Communities Team, et publié il y a 10 mois.
Funding for the Rare Disease Communities project comes from several types of sources such as patient organisations (AFM), public funds (EAHC), corporate syndicates (LEEM) and pharmaceutical companies. All funding supports the project as a whole and plays an essential part in launching and sustaining all participating rare disease communities.
 |
AFM (French Association for Neuromuscular Disorders) |
 |
LEEM (Les Entreprises du medicament) |
  |
European Commission DG Health and Consumers |
 |
Alexion Pharmaceuticals |
 |
Celgene Corporation |
 |
|
 |
GSK |
 |
Millennium, The Takeda Oncology Company |
 |
Novartis |
 |
Pfizer |
 |
Medtronic Foundation |
The material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.
Ecrit par Rare Disease Communities Team, et publié il y a 10 mois.
